Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Study Status: 
Open
Study Description: 

This clinical trial is for men and women age 18 and older who have severe aortic valve stenosis and are scheduled to undergo a Transcatheter Aortic Valve Replacement procedure ("TAVR," also known as Transcatheter Aortic Valve Implantation or "TAVI").

The purpose of the study is to evaluate the safety and efficacy of the Sentinel™ Cerebral Protection System made by Claret Medical, Inc. The Sentinel system is intended to capture and remove blood clots that may form during a TAVR procedure so as to protect the brain from possible damage due to blockage of the arteries that supply blood to the brain.

Study subjects will be followed up for 90 days after the TAVR procedure.

Key Eligibility: 

Men and women age 18 and older who are diagnosed with severe symptomatic calcified native aortic valve stenosis (narrowing) and are scheduled to undergo a Transcatheter Aortic Valve Replacement procedure ("TAVR," also known as Transcatheter Aortic Valve Implantation or "TAVI") may enroll in the study.

Detailed eligibility requirements will be reviewed when you contact the study team.

Principal Investigator: 
S. Chiu Wong, M.D.
Contact: 

Dolores Reynolds, R.N., phone 212-746-4617, email dtr2001@med.cornell.edu

Sponsor: 
Claret Medical, Inc.
Official Title: 

Cerebral Protection in Transcatheter Aortic Valve Replacement: The SENTINEL Study. ClinicalTrials.gov Identifier NCT02214277

Make an Appointment

(646) 962-5558

Weill Cornell Medicine
Division of Cardiology

520 East 70th Street
Starr 443
New York, NY 10021

1305 York Avenue, 8th Floor
New York, NY 10021